[ad_1]
A British study found that tocilizumab, an arthritis drug, can help coronavirus patients with severe problems recover, and researchers found that patients who took the drug in a clinical trial conducted by the Imperial College London were 87% more likely to be cured, as symptoms improved within 28 days than patients who were not given the drug.
According to the British newspaper “The Daily Mail”, as the study is ongoing, researchers are still unsure whether tocilizumab can increase a person’s chances of survival, however, early results may help doctors determine how to treat patients. . , They said.
Tocilizumab Made by the Swiss pharmaceutical giant Roche, it’s an anti-inflammatory drug usually given to people with rheumatoid arthritis, which works in coronavirus patients by stopping a deadly “ cytokine storm ”, an overreaction of the immune system that causes inflammation..
Scientists said preliminary data indicates that the drug, priced between 500 and 1000 pounds per patient, may be better than steroids in treating patients with Corona virus, and some steroid drugs have been shown to reduce the risk of death up to a third and a drug is used. One in particular, dexamethasone, is routine NHS.
However, one drug failed tocilizumab – Which was marketed as Actemra – Showing no benefit in other studies. Independent scientists have suggested it is too early to draw conclusions.
It was an experience REMAP-CAP , Which she drove Imperial College And implemented in the UK and Europe, they are studying current medications to see if any of them can be redesigned to help cure COVID-19.
In total, more than 2,000 patients have been registered in 15 countries in more than 260 hospitals around the world, where patients are given drugs that attack the virus itself or prevent internal swelling or blood clots that can lead to strokes or attacks of heart..
.
[ad_2]
Source link
